{"id":"NCT03862807","sponsor":"Alnylam Pharmaceuticals","briefTitle":"Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant","officialTitle":"An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-27","primaryCompletion":"2020-10-06","completion":"2020-10-20","firstPosted":"2019-03-05","resultsPosted":"2021-12-21","lastUpdate":"2024-04-22"},"enrollment":24,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Amyloidosis, Familial","Transthyretin Amyloidosis"],"interventions":[{"type":"DRUG","name":"Patisiran","otherNames":["ALN-TTR02","ONPATTRO"]}],"arms":[{"label":"Patisiran","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of patisiran in participants with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with disease progression after liver transplant.","primaryOutcome":{"measure":"Average of Month 6 and Month 12 Percentage Reduction From Baseline in Serum Transthyretin (TTR)","timeFrame":"Baseline, Months 6 and 12","effectByArm":[{"arm":"Patisiran","deltaMin":91,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":9,"countries":["France","Germany","Italy","Portugal","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["37639169","35213769","35188911"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":23},"commonTop":["Diarrhoea","Infusion related reaction","Oedema peripheral","Back pain","Fatigue"]}}